Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Zara Izadi, MPHarm, MAS; Erica J. Brenner, MD; Satveer K. Mahil, PhD; Nick Dand, PhD; Zenas Z. N. Yu, MBChB, PhD; Mark Yates, PhD; Ryan C. Ungaro, MD, MS; Xian Zhang, PhD; Manasi Agrawal, MD; Jean-Frederic Colombel, MD; Milena A. Gianfrancesco, MPH, PhD; Kimmie L. Hyrich, MD, PhD; Anja Strangfeld, MD, PhD; Loreto Carmona, MD, PhD; Elsa F. Mateus, PhD; Saskia Lawson-Tovey, BA; Eva Klingberg, MD, PhD; Giovanna Cuomo, MD; Marta Caprioli, MD; Ana Rita Cruz-Machado, MD; Ana Carolina Mazeda Pereira, MD; Rebecca Hasseli, MD; Alexander Pfeil, MD; Hanns-Martin Lorenz, MD; Bimba Franziska Hoyer, MD; Laura Trupin, MPH; Stephanie Rush, BA; Patricia Katz, PhD; Gabriela Schmajuk, MD, MS; Lindsay Jacobsohn, BA; Andrea M. Seet, MPH; Samar Al Emadi, MBBS; Leanna Wise, MD; Emily L. Gilbert, MD, PhD; Emily L. Gilbert, MD, PhD; Ali Duarte-Garcia, MD, MSc; Maria O. Valenzuela-Almada, MD; Carolina A. Isnardi, MD; Rosana Quintana, MD, MSc, PhD; Enrique R. Soriano, MD, MSc; Tiffany Y.T. Hsu, MD, PhD; Kristin M. D'Silva, MD; Jeffrey A. Sparks, MD, MMS; Naomi J. Patel, MD; Ricardo Machado Xavier, MD, PhD; Claudia Diniz Lopes Marques, PhD; Adriana Maria Kakehashi, MD, PhD; René-Marc Filpo, MD, PhD; Pascal Claudepierre, MD, PhD; Alain Cantagrel, MD, PhD; Philippe Goupille, MD, PhD; Zachary S. Wallace, MD, MSc; Suleman Bhana, MD; Wendy Costello; Rebecca Hasseli, MD, PhD; Jonathan S. Hausmann, MD; Jean W. Liew, MD, MS; Emily Sirotich, BSc; Paul Sufka, MD; Philip C. Robinson, MBChB, PhD; Pedro M. Machado, MD, PhD; Christopher E. M. Griffiths, MD; Jonathan S. Hausmann, MD; Catherine H. Smith, MD; Jinoos Yazdany, MD, MPH; Michael D. Kappelman, MD, MPH; A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included.

RESULTS A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age of patients was 63 years (±15 years). The main outcome was COVID-19–associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations.

EXPOSURES Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, and Janus kinase (Jak) inhibitor monotherapy.

MAIN OUTCOMES AND MEASURES The main outcome was COVID-19–associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations.

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.
was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients [35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1.17-2.58; \( P = .006 \)), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; \( P = .001 \)), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; \( P < .001 \)), and Jak inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; \( P = .004 \)) but not among those who received a TNF inhibitor in combination with methotrexate therapy (OR, 1.18; 95% CI, 0.85-1.63; \( P = .33 \)). Similar findings were obtained in analyses that accounted for potential reporting bias and sensitivity analyses that excluded patients with a COVID-19 diagnosis based on symptoms alone.

CONCLUSIONS AND RELEVANCE In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs.

Introduction

Patients with COVID-19, caused by SARS-CoV-2, can have mild symptoms or experience a severe and/or life-threatening infection.\(^1\) Comorbidities, such as lung disease, diabetes, and obesity, increase the risk of adverse COVID-19 outcomes.\(^2\) Any benefits of treatments for immune-mediated inflammatory diseases (IMIDs) for COVID-19 outcomes remain a topic of interest. These treatments impact the immune system and are associated with a higher risk of infections overall.\(^3\) This association raises concern about impaired immune response to SARS-CoV-2 among patients currently receiving treatment for IMIDs. However, many damaging consequences of SARS-CoV-2 infection are produced by a hyperinflammatory response.\(^4\) Therefore, treatments that target an overactive immune response may have protective benefits against adverse COVID-19 outcomes.\(^1,4\)

Tumor necrosis factor (TNF) inhibitors, a class of biologic therapies that target the proinflammatory cytokine TNF, are first- or second-line treatments for many IMIDs. International registries of patients with IMIDs have provided initial information regarding COVID-19 outcomes among individuals who received TNF inhibitor therapies during the pandemic. An analysis of data from the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry, which includes patients with inflammatory bowel disease (IBD) who were diagnosed with COVID-19, found that prevalent use compared with no use of TNF inhibitors at COVID-19 diagnosis was not associated with severe COVID-19 (odds ratio [OR], 0.9; 95% CI, 0.4-2.2).\(^5\) A study of data from the Global Rheumatology Alliance (GRA) physician-reported registry of COVID-19 outcomes among people with rheumatic diseases found that prevalent use compared with no use of TNF inhibitors at COVID-19 diagnosis was associated with lower odds of COVID-19-associated hospitalization (OR, 0.40; 95% CI, 0.19-0.81).\(^6\) An analysis of data from the Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect) also found higher odds of hospitalization among patients treated with nonbiologic systemic therapies compared with biologic therapies, including TNF inhibitors (OR, 2.84; 95% CI, 1.31-6.18).\(^7\) Although studies of individual registries have provided initial information, they were often underpowered to perform more granular analyses of commonly used medications, such as monotherapy vs combination therapy with immunomodulatory drugs, or analyses of medications that are used less frequently.

Pooling data across registries offers an opportunity to rapidly assess any association between TNF inhibitor therapies and COVID-19 outcomes among individuals with IMIDs and to evaluate the
consistency of findings across studies and diseases. We pooled data from these 3 international registries of patients with IBD, psoriasis, and rheumatic diseases to evaluate the association between TNF inhibitor monotherapy and COVID-19–associated hospitalization or death compared with other commonly prescribed immunomodulatory regimens among individuals with IMIDs.

Methods

Registry Designs and Approvals
Details of the design of the GRA, SECURE-IBD, and PsoProtect registries have been described previously.\(^7\)\(^-\)\(^1\)\(^0\) In brief, clinicians and trained staff directly report COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs who have confirmed or suspected COVID-19 using online data entry portals. Quality is assessed by registry-specific data validation teams who remove all known or potential duplicates and address erroneous or ineligible reports. The GRA and PsoProtect registries contain only limited data; no personal identifiers, with the exception of COVID-19 diagnosis dates, are included. The SECURE-IBD registry follows the safe harbor deidentification standards of the Health Insurance Portability and Accountability Act. The GRA registry was determined to be nonhuman subjects research by the United Kingdom Health Research Authority, the University of Manchester (United Kingdom), and the University of California, San Francisco, and informed consent was therefore not required. For the SECURE-IBD registry, the Office for Human Research Ethics at the University of North Carolina at Chapel Hill determined that storage and analysis of deidentified data did not constitute human subjects research and did not require institutional review board approval or informed consent. Voluntary ethical approval was sought by the PsoProtect registry and granted by the Leeds Research Ethics Committee (United Kingdom), who determined that informed consent was not required because of the use of deidentified data. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

COVID-19 Diagnosis
Among patients with rheumatic disease, a COVID-19 diagnosis was based on polymerase chain reaction (PCR), antibody serology testing, or metagenomic testing; computed tomographic scans; laboratory assays; or symptoms alone. Among patients with IBD, a COVID-19 diagnosis was based on PCR testing, symptoms with confirmatory antibody serology testing, or rapid antigen testing. Among patients with psoriasis, both confirmed and suspected COVID-19 diagnoses were reported; however, information regarding the type of diagnostic testing used was not collected.

Exposures and Outcome
To obtain sufficient statistical power, each exposure category was required to have more than 250 patients in the pooled analysis. Exposure was defined as a categorical variable that comprised the following categories: TNF inhibitor (including adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) monotherapy (reference category), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor (including tofacitinib, baricitinib, and upadacitinib) monotherapy. The outcome of interest was hospitalization or death associated with COVID-19.

Inclusion and Exclusion Criteria
We included adults (age \(\geq 18\) years) with a diagnosis of inflammatory arthritis, IBD, or psoriasis who were reported to the GRA, SECURE-IBD, or PsoProtect registries, respectively, from March 12, 2020, to February 1, 2021. Our analysis included reconciled patients only. For the GRA registry, reconciled patients were defined as those with at least 1 of the following recorded outcomes: death, symptoms resolved at the time of data entry, not hospitalized more than 30 days after the initial diagnosis date,
hospitalized and discharged, or not at risk of further interventions or death. For the SECURE-IBD and PsoProtect registries, patients were defined as reconciled after a minimum of 7 days or 14 days, respectively, or if sufficient time had passed to observe the disease course through the resolution of acute illness or death.

To limit confounding from other immunomodulatory medications, we excluded patients who received an exposure treatment regimen as well as concomitant immunomodulatory drugs, except when sulfasalazine, mesalamine, hydroxychloroquine or chloroquine, leflunomide, oral budesonide, or glucocorticoids were used as concomitant medications.

**Statistical Analysis**

We used descriptive statistics to summarize the demographic and clinical characteristics of the study population. Continuous variables were reported as means with SDs or medians with 25th and 75th percentiles, as appropriate. Categorical variables were reported as numbers with percentages. We performed registry-level analyses and a pooled analysis of data across the 3 registries to estimate independent associations between exposure categories and COVID-19 outcomes. Registry-level effect estimates were reported for exposure categories that included 10 or more patients. Associations were estimated using multilevel multivariable mixed-effects logistic regression analysis and reported as odds ratios (ORs) with 95% CIs. We chose mixed-effects regression analysis for its ability to handle missing data using maximum-likelihood estimation and to fit nested random effects to account for multilevel clustering.11

Covariates included in all models were age, sex, current smoking, IMID activity (remission vs active disease, as reported by the clinician), important comorbidities (cardiovascular disease [including coronary artery disease, heart failure, and arrhythmia], diabetes, hypertension, obstructive lung disease [including chronic obstructive pulmonary disease and asthma], interstitial or other chronic lung disease, kidney disease [including chronic kidney insufficiency and end-stage kidney disease], obesity [defined as body mass index \( \geq 30 \); calculated as weight in kilograms divided by height in meters squared], and cancer, each included as a dichotomous variable), and prednisone-equivalent glucocorticoid dose (included as a continuous variable). For the registry-level analyses, we included the following concomitant medications: sulfasalazine, hydroxychloroquine or chloroquine, and leflunomide for the GRA analysis and mesalamine, sulfasalazine, and oral budesonide for the SECURE-IBD analysis. If any of these concomitant medications were significant confounders (\( P < .05 \)) in the registry-level analyses, they were also included as covariates in the pooled analysis; patients from registries that did not include the respective concomitant medications were assigned to the category of individuals with nonuse of these medications. Registry-level analyses also controlled for disease diagnosis; diagnoses in the GRA registry included rheumatoid arthritis (reference category), psoriatic arthritis, spondyloarthritis, and other inflammatory arthritis or more than 1 type of inflammatory arthritis, and diagnoses in the SECURE-IBD registry included Crohn disease (reference category), ulcerative colitis, and unspecified IBD.

We fitted country-level random effects to account for within-country correlations. To account for changes in COVID-19 treatment and health service use over time, we also fitted random effects for the calendar month of symptom onset (PsoProtect registry) or the calendar month during which the patient was diagnosed (GRA registry) or reported (SECURE-IBD registry). The pooled model also included registry-level random effects accounting for within-registry correlations. The hierarchical order of nested random effects in the pooled model was country followed by time and registry. To improve model fit, we removed influential statistical outliers identified in continuous variables (ie, age and glucocorticoid dose) from the analyses. As a result, 2 patients were removed who received a daily prednisone dose greater than 70 mg.

All analyses were conducted using Stata software, version 16.0 (StataCorp). The threshold for statistical significance was 2-sided \( P < .05 \).

Rheumatology clinics from 2 large health care systems (Mass General Brigham in Massachusetts and Mayo Clinic in Minnesota and Florida) had processes in place to systematically report all patients
with COVID-19 to the GRA registry. To assess the extent of potential reporting bias arising from convenience sampling, ORs were derived after reweighting the covariate distribution of patients in the GRA registry to those of the 2 health care systems using the inverse odds of sampling weights technique, and those values were compared with the original ORs using standardized difference. In addition, to assess the robustness of results, a pooled sensitivity analysis was performed after excluding patients with a COVID-19 diagnosis that was based on symptoms alone.

Results

As of February 1, 2021, 8268 patients were reported to have received an exposure treatment regimen at COVID-19 diagnosis. Of those, 5220 patients were from the GRA registry, 2720 patients were from the SECURE-IBD registry, and 328 patients were from the PsoProtect registry. A total of 6077 patients from 74 countries met study eligibility criteria and were included in the analyses; of those, 3441 patients (56.6%) were from the GRA registry, 2336 patients (38.4%) were from the SECURE-IBD registry, and 300 patients (4.9%) were from the PsoProtect registry. Of the 2191 patients excluded from the analyses, most were excluded because they had a rheumatic disease diagnosis other than inflammatory arthritis (827 patients), were patients who were nonreconciled (581 patients), or received concomitant medications that were listed in the exclusion criteria (551 patients) (Table 1).

The demographic and clinical characteristics of the 6077 patients included in the analysis are shown in Table 2. Most patients were from Europe (3215 individuals [52.9%]) and North America (2015 individuals [33.2%]), and the mean (SD) age was 48.8 (16.5) years; 3563 patients (58.6%) were female, and 2468 patients (40.6%) were male. Race and ethnicity were not addressed in these analyses because information on race was not recorded in the PsoProtect registry, and information on race and ethnicity was not available for all countries in the GRA registry. The most common

Table 1. Reasons for Study Exclusion

| Reason for Study Exclusion | Total patients using an exposure treatment regimen as of February 1, 2021<sup>a</sup> | Patients excluded | Reason for exclusion |
|----------------------------|---------------------------------|------------------|---------------------|
|                             | No.                             | GRA registry     | SECURE-IBD registry | PsoProtect registry |
|-------------------------------|---------------------------------|------------------|---------------------|
| Total patients using an exposure treatment regimen as of February 1, 2021<sup>a</sup> | 8268                           | 5220             | 2720                | 328                |
| Patients excluded             | 2191                           | 1779             | 384                 | 28                 |
| Reason for exclusion          |                                 |                  |                     |                    |
| Age missing or <18 y          | 230                            | 0                | 226                 | 4                  |
| Nonreconciled<sup>b</sup>     | 581                            | 581              | 0                   | 0                  |
| Noninflammatory arthritis diagnosis | 827                      | 827              | NA                  | NA                 |
| Receipt of concomitant medication listed in exclusion criteria<sup>c</sup> | 551                            | 370              | 157                 | 24                 |
| Influential statistical outliers<sup>d</sup> | 2                              | 1                | 1                   | 0                  |

Abbreviations: GRA, COVID-19 Global Rheumatology Alliance; PsoProtect, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection; SECURE-IBD, Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease.

<sup>a</sup> Exposure treatment regimens included tumor necrosis factor (TNF) inhibitor monotherapy, TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase inhibitor monotherapy.

<sup>b</sup> In the GRA registry, a patient was defined as reconciled if at least 1 of the following criteria were present: deceased, symptoms resolved at the time of data entry, not hospitalized >30 days after the initial diagnosis date, hospitalized and discharged, or not at risk of further interventions or death. In the SECURE-IBD and PsoProtect registries, a patient was defined as reconciled after a minimum of 7 days or 14 days, respectively, or if sufficient time had passed to observe the disease course through resolution of acute illness or death.

<sup>c</sup> Excluded concomitant medications included any medication with the exception of sulfasalazine, mesalamine, hydroxychloroquine or chloroquine, leflunomide, oral budesonide, or glucocorticoids.

<sup>d</sup> To improve model fit, influential statistical outliers identified in continuous variables were removed. Two patients were removed who received a daily prednisone dose >70 mg.
Table 2. Patient Characteristics and COVID-19 Outcomes

| Characteristic or outcome                                      | No. (%) | Pooled (N = 6077) | GRA (n = 3441) | SECURE-IBD (n = 2336) | PsoProtect (n = 300) |
|---------------------------------------------------------------|---------|-------------------|----------------|-----------------------|----------------------|
| Age, mean (SD), y                                            | 48.8 (16.5) | 55.0 (14.4) | 39.4 (15.4) | 49.9 (12.6) |
| Sex*                                                         |         |                   |                |                       |                      |
| Female                                                       | 3563 (58.6) | 2295 (66.7) | 1153 (49.4) | 115 (38.3)  |
| Male                                                         | 2468 (40.6) | 1144 (33.2) | 1139 (48.8) | 185 (61.7)  |
| Unknown                                                      | 46 (0.8) | 2 (0.1) | 44 (1.9) | 0 |
| Region*                                                      |         |                   |                |                       |                      |
| Africa                                                        | 24 (0.4) | 16 (0.5) | 7 (0.3) | 1 (0.3) |
| Eastern Mediterranean                                        | 191 (3.1) | 120 (3.5) | 68 (2.9) | 3 (1.0) |
| Europe                                                       | 3215 (52.9) | 1800 (52.3) | 1143 (48.9) | 272 (90.7)  |
| North America                                                | 2015 (33.2) | 1066 (31.0) | 942 (40.3) | 7 (2.3) |
| South America                                                | 502 (8.3) | 375 (10.9) | 111 (4.8) | 16 (5.3) |
| Southeast Asia                                               | 22 (0.4) | 8 (0.2) | 13 (0.6) | 1 (0.3) |
| Western Pacific                                              | 85 (1.4) | 56 (1.6) | 29 (1.2) | 0 |
| Unknown                                                      | 23 (0.4) | 0 | 23 (1.0) | 0 |
| Diagnosis*                                                   |         |                   |                |                       |                      |
| Rheumatoid arthritis only                                    | 2146 (35.3) | 2146 (62.4) | NA | NA |
| Spondyloarthritis only                                       | 624 (10.3) | 624 (18.1) | NA | NA |
| Psoriatic arthritis only                                     | 566 (9.3) | 566 (16.4) | NA | NA |
| Other inflammatory arthritis or >1 type of inflammatory arthritis | 105 (1.7) | 105 (3.1) | NA | NA |
| Crohn disease                                                | 1537 (25.3) | NA | 1537 (65.8) | NA |
| Unspecified inflammatory bowel disease                       | 37 (0.6) | NA | 37 (1.6) | NA |
| Ulcerative colitis                                           | 762 (12.5) | NA | 762 (32.6) | NA |
| Psoriasis                                                    | 300 (4.9) | NA | NA | 300 (100) |
| Disease activity*                                            |         |                   |                |                       |                      |
| Remission                                                    | 2511 (41.3) | 1067 (31.0) | 1369 (58.6) | 75 (25.0) |
| Active                                                       | 2918 (48.0) | 1829 (53.2) | 864 (37.0) | 225 (75.0) |
| Unknown                                                      | 648 (10.7) | 545 (15.8) | 103 (4.4) | 0 |
| Exposure treatment regimen*                                  |         |                   |                |                       |                      |
| TNF inhibitor monotherapy                                     | 2844 (46.8) | 1183 (34.4) | 1445 (61.9) | 216 (72.0) |
| TNF inhibitor plus methotrexate                               | 669 (11.0) | 575 (16.7) | 87 (3.7) | 7 (2.3) |
| TNF inhibitor plus azathioprine/6-mercaptopurine              | 334 (5.5) | 7 (0.2) | 327 (14.0) | 0 |
| Methotrexate monotherapy                                      | 1546 (25.4) | 1438 (41.8) | 31 (1.3) | 77 (25.7) |
| Azathioprine/6-mercaptopurine monotherapy                     | 398 (6.5) | 19 (0.6) | 379 (16.2) | 0 |
| Jak inhibitor monotherapy                                     | 286 (4.7) | 219 (6.4) | 67 (2.9) | 0 |
| Concomitant medication                                       |         |                   |                |                       |                      |
| Sulfasalazine                                                | 294 (4.8) | 246 (7.1) | 48 (2.1) | NA |
| Mesalamine                                                   | 384 (6.3) | NA | 384 (16.4) | NA |
| Oral budesonide                                              | 39 (0.6) | NA | 39 (1.7) | NA |
| Leflunomide                                                  | 212 (3.5) | 212 (6.2) | NA | NA |
| Chloroquine or hydroxychloroquine                            | 316 (5.2) | 316 (9.2) | NA | NA |
| Daily glucocorticoid*                                        |         |                   |                |                       |                      |
| No                                                           | 114 (1.9) | 2650 (77.0) | 2212 (94.7) | 300 (100) |
| Yes                                                          | 5162 (84.9) | 681 (19.8) | 118 (5.1) | 0 |
| Unknown                                                      | 801 (13.2) | 108 (3.1) | 6 (0.3) | 0 |
| Daily prednisone-equivalent glucocorticoid, median (25th percentile-75th percentile), mg | 5 (5.0-10.0) | 5 (5.0-7.5) | 20.0 (5.0-36.0) | NA |

(continued)
disease diagnoses were rheumatoid arthritis (2146 patients [35.3%]), Crohn disease (1537 patients [25.3%]), ulcerative colitis (762 patients [12.5%]), and spondyloarthritis (624 patients [10.3%]). The most common comorbidities were hypertension (1360 patients [22.4%]), diabetes (541 patients [8.9%]), obstructive lung disease (430 patients [7.1%]), and cardiovascular disease (388 patients [6.4%]). Current smoking and obesity were substantially more prevalent among patients in the PsoProtect registry (42 patients [14.0%] and 92 patients [30.7%], respectively) compared with those in the GRA registry (153 patients [4.4%] and 673 patients [19.6%]) or the SECURE-IBD registry (100 patients [4.3%] and 385 patients [16.5%]).

The receipt of TNF inhibitor monotherapy was reported in 1183 patients (34.4%) from the GRA registry, 1445 patients (61.9%) from the SECURE-IBD registry, and 216 patients (72.0%) from the PsoProtect registry (Table 2). Methotrexate monotherapy was the most prevalent treatment regimen at COVID-19 diagnosis among patients from the GRA registry (1438 individuals [41.8%]). The receipt of azathioprine/6-mercaptopurine, alone or in combination with a TNF inhibitor, was reported in a small proportion of patients from the GRA registry (26 individuals [0.8%]) and in 0 patients from the PsoProtect registry. The receipt of Jak inhibitor monotherapy was reported in 219 patients (6.4%) from the GRA registry, 67 patients (2.9%) from the SECURE-IBD registry, and 0 patients from the PsoProtect registry. A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died (Table 2). Both hospitalizations and deaths were more common among patients from the GRA registry (939 patients [27.3%] and 166 patients [4.8%], respectively) than the SECURE-IBD registry (316 patients [13.5%] and 20 patients [0.9%]) or the PsoProtect registry (42 patients [14.0%] and 3 patients [1.0%]).
Along with the prespecified covariates, the concomitant medications sulfasalazine, leflunomide, and oral budesonide were included in the pooled multivariable model because these medications were significantly associated with hospitalization or death in the GRA (sulfasalazine: OR, 1.55 [95% CI, 1.03-2.35; P = .04]; leflunomide: OR, 1.97 [95% CI, 1.22-3.18; P = .005]) or the SECURE-IBD (oral budesonide: OR, 2.71; 95% CI, 1.11-6.60; P = .03) registry-level analyses. In the pooled analysis, compared with TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (OR, 1.74; 95% CI, 1.17-2.58; P = .006). Differences in the odds of hospitalization or death among those who received TNF inhibitor monotherapy vs a TNF inhibitor in combination with methotrexate therapy were not statistically significant in the registry-specific analyses (GRA: OR, 1.20 [95% CI, 0.80-1.79; P = .38]; SECURE-IBD: OR, 1.59 [95% CI, 0.76-3.34; P = .22]) or the pooled analysis (OR, 1.18; 95% CI, 0.85-1.63; P = .33). Compared with those who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P < .001), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P = .001), and Jak inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; P = .004) in the pooled analysis.

Although ORs obtained from registry-specific analyses were generally in the same direction and of similar extent as those obtained from the pooled analysis, we observed some notable differences (Figure and eTable in Supplement 1). Odds ratios for methotrexate monotherapy compared with TNF inhibitor monotherapy were larger among patients in the PsoProtect registry than patients in the SECURE-IBD or the GRA registries. Odds ratios for azathioprine/6-mercaptopurine monotherapy compared with TNF inhibitor monotherapy were larger among patients in the GRA registry than patients in the SECURE-IBD registry. In addition, the receipt of Jak inhibitor monotherapy was not associated with higher odds of hospitalization or death compared with TNF inhibitor monotherapy (OR, 0.60; 95% CI, 0.22-1.64; P = .32) among patients in the SECURE-IBD registry.

Other factors associated with higher odds of hospitalization or death in the pooled analysis included older age (OR per 1 year increase in age, 1.04; 95% CI, 1.04-1.05; P < .001); active IMID at COVID-19 diagnosis (OR, 1.27; 95% CI, 1.04-1.55; P = .02); obesity (OR, 1.39; 95% CI, 1.10-1.75; P = .005); lung disease (interstitial: OR, 1.81 [95% CI, 1.12-2.95; P = .02]; obstructive: OR, 2.34 [95% CI, 1.69-3.24; P < .001]); cardiovascular disease (OR, 1.58; 95% CI, 1.13-2.21; P = .007); diabetes (OR, 1.54; 95% CI, 1.16-2.05; P = .003); chronic kidney disease (OR, 3.10; 95% CI, 1.70-5.66; P < .001); concomitant use of sulfasalazine (OR, 1.62; 95% CI, 1.13-2.34; P = .009), leflunomide (OR, 1.89; 95% CI, 1.20-2.99; P = .006), or oral budesonide (OR, 2.86; 95% CI, 1.20-6.84; P = .02); and higher daily prednisone-equivalent glucocorticoid dose (OR per 1 mg increase in dose, 1.07; 95% CI, 1.05-1.08; P < .001) (Table 3). Female sex was associated with a protective benefit (OR, 0.79; 95% CI, 0.66-0.96; P = .02). The intraclass correlation coefficient was 0.27 (95% CI, 0.20-0.36), suggesting that clustering of patients within country, calendar month, and registry explained 27% of the variation in the odds of hospitalization or death. Complete results from registry-specific analyses are shown in the eTable in Supplement 1.

We compared GRA registry-specific results with results obtained after reweighting the covariate distribution of the GRA population to match those of rheumatology clinics that systematically reported all patients diagnosed with COVID-19. Standardized differences between the reweighted and original estimates were in the acceptable range of less than 0.14 (0.035 for log OR corresponding to TNF inhibitor in combination with methotrexate therapy compared with TNF inhibitor monotherapy; 0.002 for log OR corresponding to methotrexate monotherapy compared with TNF inhibitor monotherapy; 0.072 for log OR corresponding to Jak inhibitor monotherapy compared with TNF inhibitor monotherapy), suggesting that reporting bias was minimal in the GRA registry (Table 4).

A total of 864 patients (14.2%; 112 patients [37.3%] from the PsoProtect registry, 752 patients [21.9%] from the GRA registry, and 0 patients from the SECURE-IBD registry) received a COVID-19
diagnosis based on symptoms alone. Our pooled results remained consistent in a sensitivity analysis that excluded these patients (Figure).

**Discussion**

This cohort study found that TNF inhibitor monotherapy was associated with a lower risk of COVID-19–associated hospitalization or death among patients with IMIDs compared with other commonly used treatment regimens, including methotrexate, azathioprine/6-mercaptopurine, and Jak inhibitors. After controlling for active disease and common comorbidities, the odds of hospitalization or death among those who received TNF inhibitor combination therapies vs TNF inhibitor monotherapy depended on the type of additional medication used in the combination regimen. Patients receiving TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy had higher odds of hospitalization or death compared with those receiving TNF inhibitor monotherapy.

![Figure. Adjusted Odd Ratios (ORs) of COVID-19–Associated Hospitalization or Death Among Patients Receiving Immunomodulatory Treatment Regimens vs Tumor Necrosis Factor Inhibitor (TNFi) Monotherapy](https://jamanetwork.com/)

| Treatment regimen | OR (95% CI) | Favors other regimen | Favors TNFi monotherapy |
|-------------------|-------------|----------------------|-------------------------|
| TNFi plus AZA/6MP vs TNFi monotherapy | | |
| SECURE-IBD registry | 1.51 (0.98-2.31) | | |
| Pooled estimate (primary analysis) | 1.74 (1.17-2.58) | | |
| Pooled estimate (sensitivity analysis) | 1.57 (1.06-2.35) | | |
| TNFi plus MTX vs TNFi monotherapy | | |
| GRA registry | 1.20 (0.80-1.79) | | |
| SECURE-IBD registry | 1.59 (0.76-3.34) | | |
| Pooled estimate (primary analysis) | 1.18 (0.85-1.63) | | |
| Pooled estimate (sensitivity analysis) | 1.14 (0.81-1.60) | | |
| AZA/6MP monotherapy vs TNFi monotherapy | | |
| GRA registry | 5.28 (1.51-18.43) | | |
| SECURE-IBD registry | 1.50 (1.00-2.24) | | |
| Pooled estimate (primary analysis) | 1.84 (1.30-2.61) | | |
| Pooled estimate (sensitivity analysis) | 1.69 (1.19-2.39) | | |
| MTX monotherapy vs TNFi monotherapy | | |
| GRA registry | 2.21 (1.59-3.08) | | |
| SECURE-IBD registry | 2.66 (1.95-4.33) | | |
| PsoProtect registry | 8.76 (2.94-26.06) | | |
| Pooled estimate (primary analysis) | 2.00 (1.57-2.56) | | |
| Pooled estimate (sensitivity analysis) | 2.10 (1.62-2.72) | | |
| JAKi monotherapy vs TNFi monotherapy | | |
| GRA registry | 2.41 (1.46-3.99) | | |
| SECURE-IBD registry | 0.60 (0.22-1.64) | | |
| Pooled estimate (primary analysis) | 1.82 (1.21-2.73) | | |
| Pooled estimate (sensitivity analysis) | 1.77 (1.16-2.69) | | |

Registry-specific and pooled analyses, with TNFi monotherapy used as the reference category. Pooled estimates were obtained using hierarchical multivariable mixed-effects logistic regression analysis with registry and calendar month random effects nested within country. Pooled sensitivity analysis (n = 5213) excludes patients with a presumptive COVID-19 diagnosis (defined as a diagnosis based on symptoms alone). All ORs were adjusted for age, sex, current smoking, immune-mediated disease activity (remission vs active), important comorbidities (cardiovascular disease, diabetes, hypertension, obstructive lung disease, interstitial or other chronic lung disease, kidney disease, obesity [body mass index ≥30, calculated as weight in kilograms divided by height in meters squared], and cancer), and prednisone-equivalent glucocorticoid dose. The pooled sensitivity analysis was also adjusted for concomitant receipt of leflunomide and oral budesonide. The pooled analysis (N = 6077) was additionally adjusted for concomitant receipt of sulfasalazine. The COVID-19 Global Rheumatology Alliance (GRA) registry-level analysis included 3441 patients and was adjusted for immune-mediated disease diagnosis and concomitant receipt of sulfasalazine, hydroxychloroquine or chloroquine, and leflunomide medications. The Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect) registry-level analysis included 300 patients. The Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry-level analysis included 2336 patients and was adjusted for immune-mediated disease diagnosis and concomitant receipt of mesalazine, sulfasalazine, and oral budesonide medications. AZA/6MP indicates azathioprine/6-mercaptopurine; JAKi, Janus kinase inhibitor; and MTX, methotrexate.
whereas individuals receiving TNF inhibitors in combination with methotrexate therapy had similar odds of hospitalization or death compared with those receiving TNF inhibitors alone.

The lower odds of unfavorable COVID-19 outcomes among patients receiving TNF inhibitors before SARS-CoV-2 infection has several possible explanations. Although the exact mechanism of SARS-CoV-2-associated hyperinflammation remains uncertain, high serum TNF concentrations at the time of COVID-19 admission have been associated with organ damage and worse COVID-19 outcomes. Therefore, blocking TNF could inhibit this detrimental immune response. Multiple case series reporting favorable outcomes among patients receiving TNF inhibitor therapy support this assertion. Upcoming results from clinical trials investigating the use of TNF inhibitors will enable further evaluation of the association between TNF inhibitor therapy and COVID-19 outcomes.

Other possible explanations for our findings include the consequences of non-TNF inhibitor immunosuppressive medications for COVID-19 outcomes. Thiopurine medications are associated with a higher risk of opportunistic viral infections. A study examining data from a large registry of patients with IBD found that the receipt of thiopurines, including azathioprine and 6-mercaptopurine, was associated with a higher risk of serious viral infection, specifically infection from species of the Herpesviridae. Although data regarding other viruses cannot be directly extrapolated to COVID-19, this higher risk highlights the potential for an association between thiopurine use and an increased risk of unfavorable outcomes after SARS-CoV-2 infection. Moreover, a recent study of data from the SECURE-IBD registry reported that thiopurine monotherapy and thiopurines in combination with TNF inhibitor therapy were associated with worse COVID-19 outcomes compared with TNF inhibitor monotherapy. In contrast, researchers have postulated that methotrexate therapy may decrease the cytokine storm associated with COVID-19.

### Table 3. Adjusted Pooled Odds of COVID-19–Associated Hospitalization or Death Among Patients in the 3 Registries

| Variable | OR (95% CI) | P value |
|----------|-------------|---------|
| Exposure treatment regimen<sup>b</sup> | | |
| TNF inhibitor monotherapy | 1 [Reference] | NA |
| TNF inhibitor plus methotrexate | 1.18 (0.85-1.63) | .33 |
| TNF inhibitor plus azathioprine/6-mercaptopurine | 1.74 (1.17-2.58) | .006 |
| Methotrexate monotherapy | 2.00 (1.57-2.56) | <.001 |
| Azathioprine/6-mercaptopurine monotherapy | 1.84 (1.30-2.61) | .001 |
| Jak inhibitor monotherapy | 1.82 (1.21-2.73) | .004 |
| Concomitant medication | | |
| Sulfasalazine | 1.62 (1.13-2.34) | .009 |
| Leflunomide | 1.89 (1.20-2.99) | .006 |
| Oral budesonide | 2.86 (1.20-6.84) | .02 |
| Daily prednisone-equivalent dose per 1 mg increase | 1.07 (1.05-1.08) | <.001 |
| Demographic characteristic | | |
| Female sex | 0.79 (0.66-0.96) | .02 |
| Age per year | 1.04 (1.04-1.05) | <.001 |
| Obesity (BMI ≥30) | 1.39 (1.10-1.75) | .005 |
| Current smoking | 0.77 (0.51-1.17) | .21 |
| Disease activity | | |
| Active | 1.27 (1.04-1.55) | .02 |
| Comorbidities | | |
| Interstitial lung disease | 1.81 (1.12-2.95) | .02 |
| Obstructive lung disease | 2.34 (1.69-3.24) | <.001 |
| Cardiovascular disease | 1.58 (1.13-2.21) | .007 |
| Diabetes | 1.54 (1.16-2.05) | .003 |
| Hypertension | 1.19 (0.95-1.50) | .12 |
| Kidney disease | 3.10 (1.70-5.66) | <.001 |
| Cancer | 1.16 (0.65-2.07) | .61 |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); Jak, Janus kinase; NA, not applicable; OR, odds ratio; TNF, tumor necrosis factor.

* All 6077 patients from the COVID-19 Global Rheumatology Alliance (GRA); the Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); and the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registries were included.

<sup>b</sup> Subcategories are mutually exclusive. Odds ratios were obtained using hierarchical multivariable mixed-effects logistic regression analysis with registry and calendar month random effects nested within country. Model was adjusted for all variables shown.
However, our results suggest worse outcomes associated with methotrexate monotherapy compared with TNF inhibitor monotherapy. This association could mean that TNF inhibitor therapy is exerting a protective benefit or that methotrexate therapy is exerting a harmful consequence. Notably, the direction of association was the same for methotrexate used in combination with TNF inhibitors, although the effect estimate crossed the line of no effect, which is possibly associated with the use of lower methotrexate doses in combination therapy compared with monotherapy.27,28

The timing of treatment initiation with Jak inhibitors may be an important factor associated with COVID-19 outcomes. The second iteration of the Adaptive COVID-19 Treatment Trial (ACTT-2) suggested a protective effect of treatment with baricitinib in combination with remdesivir therapy against unfavorable COVID-19 outcomes among some subgroups of patients with confirmed severe COVID-19.29 However, population-based data from patients receiving Jak inhibitors before COVID-19 diagnosis suggest worse outcomes, which is consistent with the known association between this class of medications and reductions in the innate immune response, producing impaired viral clearance.30 In our comparative analyses, we found that Jak inhibitor monotherapy was associated with higher odds of hospitalization or death than TNF inhibitor monotherapy.

### Strengths and Limitations

This study has strengths. These strengths include the robust worldwide collaboration between 3 international registries, which enabled evaluation of a large geographically diverse sample of adults with IMIDs. To our knowledge, this study is the first to pool data across registries to evaluate COVID-19 outcomes among patients with IMIDs. Pooling data increased the power of the study, allowed for more granular analyses of medications, and improved generalizability across IMIDs. Notably, our analyses controlled for active disease, which is only possible through the use of registry data because this variable is not typically available in administrative databases or electronic health records. Furthermore, clinicians or trained staff reported directly to each registry, which likely increased the accuracy of the information.

This study also has limitations. These limitations include the risk of reporting bias because the registries used convenience sampling. However, the results of our sensitivity analysis suggest that reporting bias was not a substantial concern in the GRA registry. The threshold for hospitalization and the ways in which patients are treated for COVID-19 differs over time and across regions. Such

### Table 4. Sensitivity Analysis of the Extent of Potential Reporting Bias Based on Data From the GRA Registry

| Exposure treatment regimen | Original Estimates from GRA-specific analysis | Reweighted Estimates from GRA-specific analysis | Standardized difference | Regulatory agreement | Estimate agreement |
|----------------------------|--------------------------------------------|---------------------------------------------|------------------------|---------------------|-------------------|
|                             | Original OR (95% CI)                        | OR (95% CI)                                 | P value                | OR (95% CI)         | P value            |                  |                |
| TNF inhibitor monotherapy   | 1 [Reference] NA                           | 1 [Reference] NA                           | <.001                  | NA                  | NA                | NA               | NA             |
| TNF inhibitor plus methotrexate | 1.20 (0.80-1.79)                           | 0.96 (0.57-1.64)                           | <.001                  | 0.035               | Yes               | Yes              | NA             |
| Methotrexate monotherapy    | 2.21 (1.59-3.08)                           | 2.20 (1.82-2.65)                           | <.001                  | 0.002               | Yes               | Yes              | NA             |
| Jak inhibitor monotherapy   | 2.41 (1.46-3.99)                           | 1.88 (1.44-2.45)                           | <.001                  | 0.072               | Yes               | Yes              | NA             |

Abbreviations: GRA, COVID-19 Global Rheumatology Alliance; Jak, Janus kinase; NA, not applicable; OR, odds ratio; TNF, tumor necrosis factor.

* The number of patients receiving azathioprine/6-mecaptopurine monotherapy or TNF inhibitors in combination with azathioprine/6-mecaptopurine therapy was too small in the rheumatology clinics to derive estimates for these exposure treatment regimens.

+ Estimates were obtained after reweighting the covariate distribution of patients in the GRA registry to match those of rheumatology clinics from health care systems that systematically reported all confirmed and suspected COVID-19 patients, using the inverse odds of sampling weights technique.

## Acknowledgments

The authors thank all the GRA registry participants for their valuable contributions to this project. They also thank the GRA registry investigators for their time and effort in collecting and sharing data. The authors thank the GRA registry directors for their support and encouragement throughout the project. The authors also thank the GRA registry staff for their assistance in data collection and management. The authors thank the GRA registry investigators for their time and effort in collecting and sharing data. The authors also thank the GRA registry directors for their support and encouragement throughout the project. The authors thank the GRA registry staff for their assistance in data collection and management.
differences have the potential to introduce bias if insufficiently accounted for in the analyses. Although we attempted to account for associations in hospitalization or death owing to unmeasured temporal and geographical factors, residual confounding may remain. Additional factors that we were unable to account for included duration and previous lines of IMID therapy. Furthermore, the lack of a global COVID-19 registration system limited the feasibility of including a control group. Although the case report forms were similar, the data domains across registries were not entirely uniform. For example, time and type of COVID-19 diagnosis, rheumatic disease activity, and certain comorbidities were recorded slightly differently across registries. These inconsistencies were addressed, to the extent possible, through the incorporation of registry-level random effects in multilevel modeling and through sensitivity analyses.

Conclusions

The results of this cohort study suggest that, among patients with IMIDs, receipt of TNF inhibitor monotherapy may be associated with a lower risk of COVID-19-associated hospitalization or death compared with other immunomodulatory treatment regimens. These findings support the continued use of TNF inhibitor monotherapy during the pandemic and warrant further research investigating the association of other biologic therapies with COVID-19 outcomes. Treatment with TNF inhibitor combination therapy was associated with a more favorable safety profile when methotrexate rather than azathioprine/6-mercaptopurine was used, suggesting that clinicians would benefit from weighing the risks vs benefits of deescalating treatment or changing medications when a patient is receiving concomitant TNF inhibitors and azathioprine/6-mercaptopurine.
Tumor Necrosis Factor Inhibitors and Risk of COVID-19–Associated Hospitalization or Death

Izadi, Brenner, Mahil, Yiu, Yates, Hyrich, Carmona, Cuomo, Hasseli, Lorenz, Trupin, Katz, Al Emadi, Wise, Quintana, Wallace, Bhana, Costello, Grainger, Hausmann, Sufka, Robinson, Machado, Barker, Smith, Yazdany, Kappelman.

Author Contributions: Ms Izadi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Ms Izadi and Dr Brenner share first authorship, and Drs Yazdany and Kappelman share senior authorship.

Concept and design: Izadi, Brenner, Mahil, Yiu, Yates, Hyrich, Carmona, Cuomo, Hasseli, Lorenz, Trupin, Katz, Al Emadi, Wise, Quintana, Wallace, Bhana, Costello, Grainger, Hausmann, Sufka, Robinson, Machado, Barker, Smith, Yazdany, Kappelman.

Acquisition, analysis, or interpretation of data: Izadi, Brenner, Mahil, Dand, Yiu, Ungaro, Zhang, Agrawal, Colombel, Gianfrancesco, Hyrich, Stringfellow, Mateus, Lawson-Tovey, Klingberg, Caprioli, Cruz-Machado, Mazeda Pereira, Pfeil, Lorenz, Hoyer, Trupin, Rush, Schmajuk, Jacobsohn, Seet, Al Emadi, Wise, Gilbert, Durante-Garcia, Valenzuela-Almada, Isnardi, Soriano, Hsu, D’Silva, Sparks, Patel, Xavier, Marques, Kakehasi, Filpo, Claudepierre, Cantagrel, Wass, Hoyer, Trupin, Katz, Al Emadi, Wise, Quintana, Wallace, Bhana, Costello, Grainger, Hausmann, Sufka, Robinson, Machado, Barker, Smith, Yazdany, Kappelman.
Critical revision of the manuscript for important intellectual content: Izadi, Brenner, Mahil, Dand, Yates, Ungaro, Zhang, Agrawal, Colombel, Gianfrancesco, Hyrich, Strangfeld, Carmona, Mateus, Lawson-Tovey, Klingberg, Caprioli, Cruz-Machado, Hasseli, Pfeil, Lorenz, Hoyer, Trupin, Rush, Katz, Schmajuk, Jacobsohn, Seet, Al Emadi, Wise, Gilbert, Duarte-Garcia, Isnardi, Soriario, Hsu, D'Silva, Sparks, Patel, Xavier, Marques, Kakehasi, Flipo, Claudepierre, Cantagrel, Goupille, Wallace, Bhana, Costello, Grainger, Hausmann, Liew, Sirotich, Sufka, Robinson, Machado, Griffiths, Barker, Smith, Yazdany, Kappelman.

Statistical analysis: Izadi, Brenner, Yi, Zhang, Trupin, Seet, Flipo.

Conflict of Interest Disclosures: Dr Brenner reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Mahil reported receiving grants from AbbVie, Celgene, Eli Lilly and Company, Janssen-Cilag, Novartis, Sanofi, and UCB outside the submitted work. Dr Yates reported receiving personal fees from AbbVie and UCB. Dr Ungaro reported receiving personal fees from AbbVie, Bristol Myers Squibb, Janssen Pharmaceuticals, and Pfizer and nonfinancial support from Takeda Pharmaceutical during the conduct of the study. Dr Agrawal reported receiving grants from the Dickler Family Fund, the Helmsley Charitable Trust, and the New York Community Trust during the conduct of the study. Dr Colombel reported receiving grants from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Pharm, Eli Lilly and Company, Genentech, the Helmsley Charitable Trust, Janssen Pharmaceuticals, Pfizer, and Takeda Pharmaceutical during the conduct of the study; grants from AbbVie, Janssen Pharmaceuticals, and Takeda Pharmaceutical; and personal fees from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Ferring Pharmaceuticals, Galmed Pharmaceuticals, GlaxoSmithKline, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos Biopharma, Otsuka Pharmaceutical, Pfizer, Prometheus Biosciences, Sanofi, Takeda Pharmaceutical, and TiGenix outside the submitted work. Dr Gianfrancesco reported receiving grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases outside the submitted work. Dr Hyrich reported receiving grants from the European Alliance of Associations for Rheumatology during the conduct of the study; grants from Bristol Myers Squibb and Pfizer; and personal fees from AbbVie outside the submitted work. Dr Strangfeld reported receiving grants from AbbVie, Amgen, Bristol Myers Squibb, Celltrion Pharm, Eli Lilly and Company, Fresenius Kabi, Gilead Sciences, Hexal, Merck Sharp & Dohme, Mylan/Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB and personal fees from AbbVie, Bristol Myers Squibb, Celltrion Pharm, Eli Lilly and Company, and Pfizer, Roche, and UCB outside the submitted work. Dr Carmona reported receiving grants from AbbVie, Gebro Pharma, Grünenthal, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi Aventis, and UCB outside the submitted work. Dr Mateus reported receiving grants from AbbVie, A. Menarini Diagnostics, Amgen, Eli Lilly and Company, Grünenthal, Medac Pharma, Merck Sharp & Dohme, Novartis, and Pfizer and personal fees from Boehringer Ingelheim outside the submitted work. Dr Cruz-Machado reported receiving grants from Merck Sharp & Dohme outside the submitted work. Dr Hasseli reported receiving grants from Justus Liebig University during the conduct of the study. Dr Wise reported receiving personal fees from Aurinia Pharmaceuticals outside the submitted work. Dr Duarte-Garcia reported receiving grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation outside the submitted work. Dr Isnardi reported receiving grants from AbbVie, Laboratorio Elea Phoenix, and Pfizer during the conduct of the study and personal fees from Bristol Myers Squibb outside the submitted work. Dr Soriano reported receiving grants from Novartis, Pfizer, Roche, and UCB and personal fees from AbbVie, Amgen, Eli Lilly and Company, Janssen Pharmaceuticals, Novartis, Pfizer, and Sandoz outside the submitted work. Dr Sparks reported receiving grants from the National Institutes of Health and the Rheumatology Research Foundation and personal fees from Bristol Myers Squibb, Gilead Sciences, Inova Diagnostics, Optum, and Pfizer outside the submitted work. Dr Patel reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Xavier reported receiving personal fees from AbbVie, Eli Lilly and Company, Novartis, Pfizer, and UCB outside the submitted work. Dr Kakehasi reported receiving grants from the National Council for Scientific and Technological Development during the conduct of the study; personal fees from AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Novartis, Pfizer, Sandoz, and UCB outside the submitted work. Dr Filpo reported receiving personal fees from AbbVie, Janssen Pharmaceuticals, Merck Sharp & Dohme, and Pfizer outside the submitted work. Dr Claudepierre
reported receiving personal fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Galapagos, Janssen Pharmaceuticaal, Merck & Co, Novartis, Pfizer, Roche, Chugai, and UCB outside the submitted work. Dr Goupille reported receiving personal fees from AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Janssen Pharmaceuticaal, Novartis, Pfizer, and UCB outside the submitted work. Dr Wallace reported receiving grants from Bristol Myers Squibb and Sanofi and personal fees from Medpace Holdings and Viela Bio outside the submitted work. Dr Bhana reported receiving personal fees from AbbVie, Amgen, Horizon Therapeutics, Novartis, and Pfizer outside the submitted work. Dr Grainger reported receiving personal fees from AbbVie, Cornerstone Pharmaceuticals, Janssen Pharmaceuticals, Novartis, and Pfizer and nonfinancial support from Pfizer outside the submitted work. Dr Hausmann reported receiving grants from the Childhood Arthritis and Rheumatology Research Alliance and the Rheumatology Research Foundation and personal fees from Biogen, Novartis, and Pfizer outside the submitted work. Dr Liew reported receiving grants from Pfizer outside the submitted work. Ms Sirotich reported receiving grants from the COVID-19 Global Rheumatology Alliance and serving as a board member of the Canadian Arthritis Patient Alliance outside the submitted work. Dr Robinson reported receiving grants from Janssen Pharmaceuticals and Novartis and personal fees from AbbVie, Atom Bioscience, BMC Pharma, Eli Lilly and Company, Gilead Sciences, Pfizer, Roche, and UCB outside the submitted work. Dr Machado reported receiving grants from Orphazyme and personal fees from AbbVie, Eli Lilly and Company, Galapagos, Novartis, Orphazyme, and UCB outside the submitted work. Dr Griffiths reported receiving grants from the National Institute for Health Research during the conduct of the study; grants from Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, and LEO Pharma; and personal fees from AbbVie, Almirall, Bristol Myers Squibb, Novartis, and UCB outside the submitted work. Dr Barker reported receiving personal fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Samsung Pharmaceutical, Sienna Biopharmaceuticals, Sun Pharmaceutical Industries, and UCB outside the submitted work. Dr Smith reported receiving grants from Gu’s and St Thomas’ Biomedical Research Centre and the Psoriasis Association during the conduct of the study and grants from the Horizon 2020 Initiative and the Medical Research Council outside the submitted work. Dr Yazdany reported receiving grants from the American College of Rheumatology, Gilead Sciences, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases during the conduct of the study; grants from AstraZeneca and Bristol Myers Squibb; and personal fees from Aurinia Pharmaceuticals, Eli Lilly and Company, and Pfizer outside the submitted work. Dr Kappelman reported receiving grants from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Pharm, Eli Lilly and Company, Genentech, Janssen Pharmaceuticals, Pfizer, and Takeda Pharmaceutical during the conduct of the study; personal fees from AbbVie, Eli Lilly and Company, Johnson & Johnson, Pfizer, and Takeda Pharmaceutical; and owning shares in Johnson & Johnson outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by funding to the COVID-19 Global Rheumatology Alliance from the American College of Rheumatology and the European League Against Rheumatism and funding to the Members of Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection from the Department of Health (via the National Institute for Health Research Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, United Kingdom), the National Institute for Health Research Manchester Biomedical Research Centre, and the Psoriasis Association.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: Members of the Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA) are listed in Supplement 2.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent the views of the American College of Rheumatology, the Department of Health and Social Care (United Kingdom), the European Alliance of Associations for Rheumatology, the National Health Service (United Kingdom), or the National Institute for Health Research (United Kingdom).

Additional Contributions: We acknowledge the members of Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect), the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD), and the COVID-19 Global Rheumatology Alliance (GRA) for their assistance with development and promotion of the registries.

REFERENCES
1. Stallmach A, Kortgen A, Gonnert F, Coldewey SM, Reuken P, Bauer M. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series. Crit Care. 2020;24(1):444. doi:10.1186/s13054-020-03158-0
2. Centers for Disease Control and Prevention. People with certain medical conditions. Centers for Disease Control and Prevention; 2020. Updated August 20, 2021. Accessed January 7, 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

3. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251-260. doi:10.1136/pgmj.2006.052688

4. Robinson PC, Liew DL, Liew JW, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med (N Y). 2020;1(1):90-102.

5. Brenner EJ, Ungaro RC, Garry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481-491. doi:10.1053/j.gastro.2020.05.032

6. Gianfrancesco M, Hyrich KL, Al-Adely S, et al; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi:10.1136/annrheumdis-2020-217871

7. Mahil SK, Dand N, Mason KJ, et al; PsoProtect Study Group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71. doi:10.1016/j.jaci.2020.10.007

8. Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020;16(6):293-294. doi:10.1038/s41584-020-0418-0

9. Wallace ZS, Bhana S, Hausmann JS, et al. The rheumatology community responds to the COVID-19 pandemic: the establishment of the COVID-19 Global Rheumatology Alliance. Rheumatology (Oxford). 2020;59(6):1204-1206. doi:10.1093/rheumatology/keaa191

10. Gianfrancesco MA, Hyrich KL, Gossec L, et al; COVID-19 Global Rheumatology Alliance Steering Committee. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020;2(5):e250-e253. doi:10.1016/S2665-9913(20)30095-3

11. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. Springer; 2012. doi:10.1007/978-1-4614-1353-0

12. Westreich D, Edwards JK, Lesko CR, Stuart E, Cole SR. Transportability of trial results using inverse odds of transportability weights. Stat Med. 2016;35(28):4978-4992. doi:10.1002/sim.7571

13. Franklin JM, Pawar A, Martin D, et al. Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project. Clin Pharmacol Ther. 2020;107(4):817-826. doi:10.1002/cpt.1633

14. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107. doi:10.1002/sim.3697

15. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. doi:10.1038/s41591-020-1051-9

16. Dolinger MT, Person H, Smith R, et al. Pediatric Crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J Pediatr Gastroenterol Nutr. 2020;71(2):153-155. doi:10.1097/MPG.0000000000002809

17. Rodriguez-Lago I, Ramirez de la Piscina P, Elorza A, Merino O, Ortiz de Zarate J, Cabriada JL. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology. 2020;159(2):781-783. doi:10.1053/j.gastro.2020.04.043

18. A phase 2 trial of infliximab in coronavirus disease 2019 (COVID-19). ClinicalTrials.gov identifier: NCT04425538. Updated February 18, 2021. Accessed January 7, 2020. https://clinicaltrials.gov/ct2/show/NCT04425538

19. AVID-CC Trial Investigators. AVID-CC: adalimumab for coronavirus in community care. Websites for OCTRU Trials; 2020. Accessed January 7, 2020. https://avid-cc.octr.u.ox.ac.uk/

20. Goodson TM, Costello SP, Bryant RV. COVID-19 and implications for thiopurine use. Med J Aust. 2020;212(10):490. doi:10.5694/mja2.50613

21. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337-346. doi:10.1053/j.gastro.2018.04.012

22. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929-936. doi:10.1053/j.gastro.2008.01.012
SUPPLEMENT 1.

eTable. Adjusted Registry-Specific Odds of COVID-19-Associated Hospitalization or Death

SUPPLEMENT 2.

Nonauthor Collaborators. Members of the Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA)